Los Angeles Capital Management LLC Sells 70,967 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Los Angeles Capital Management LLC cut its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 43.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 93,360 shares of the company’s stock after selling 70,967 shares during the quarter. Los Angeles Capital Management LLC owned about 0.30% of Medpace worth $31,017,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. R Squared Ltd bought a new stake in Medpace in the fourth quarter worth $30,000. Stone House Investment Management LLC bought a new stake in Medpace in the third quarter worth $33,000. Ashton Thomas Securities LLC bought a new stake in Medpace in the third quarter worth $37,000. Capital Performance Advisors LLP bought a new stake in Medpace in the third quarter worth $46,000. Finally, True Wealth Design LLC boosted its holdings in Medpace by 16,800.0% in the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after acquiring an additional 168 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird boosted their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $340.92 on Wednesday. The company has a market cap of $10.39 billion, a P/E ratio of 26.99, a PEG ratio of 3.81 and a beta of 1.36. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The stock’s fifty day moving average price is $342.87 and its 200-day moving average price is $346.24.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.